Your innovation is global The path to patients is local

GCC Partner ∙ Global calibre ∙ Regional intelligence ∙ Local delivery

Book Your Diagnostic
Why Veridian?

Approval is not access

Approval opens the door; access brings innovation to patients

In the GCC, the gap between the two is where launches stall. Reimbursement, prescribing and procurement each demand a locally credible value story, and we carry that story from approval to reimbursement.
Read more about our approach to access

Formal approval

  • Registration
  • Regulatory clearance
  • Pricing
  • Market entry

Gap Where Launches Stall

The local value story

Real Access

  • Reimbursement
  • Prescribing and use
  • Procurement
  • Sustained access

Carry the value story from approval to reimbursement, not just to the border.

Three services, one local value story

Whatever the entry point, every engagement runs on the same three services

Regulatory Affairs & Market Entry

Maps the decision gates, partners and live entry requirements across the GCC.

Explore this service

HEOR & Market Access

Turns global evidence into GCC-ready value, pricing and reimbursement decisions.

Explore this service

Medical Affairs & Scientific Engagement

Builds the scientific narrative, evidence and expert relationships that make adoption credible.

Explore this service

Integrated Launch Programme

Not a fourth service. The three services above, orchestrated by one senior partner from strategy through first reimbursed sale.

Book a Diagnostic

Who we serve

However you start, one partner for the journey

Biopharma and medtech entrants

Your in-region team from day one, across regulatory, access and medical.

Discover how we work

Pharma affiliates and regional teams

Specialist GCC support in defined workstreams, alongside the capability you already have.

Discover how we work

Global teams

One senior partner for GCC launches, from strategy to first reimbursed sale.

Discover how we work

Access, medical and regulatory leads

Local depth to make your workstream land in the GCC’s decision environment.

Discover how we work

WHAT MAKES US DIFFERENT

Global calibre, regional intelligence, local access

Senior-led market access support across the GCC, combining global-standard evidence with genuine regional insight and in-country experience.

01

Senior-led

Every project is led by specialists with decades of industry experience, from the first meeting to the final deliverable.

02

End-to-end accountability

A single senior contact takes your launch from first diagnostic to reimbursement, so nothing gets lost between workstreams.

03

Integrated expertise

Regulatory, access and medical teams work from the same evidence, so your story stays consistent for every authority, payer and clinician.

04

Embedded in the GCC

Based in Dubai, with in-country expertise in Saudi Arabia and the UAE and experience across all six GCC markets.

230+

Years of industry, academia and consultancy experience

180+

Health economics models (CEA & BIA)

120+

Value / HTA dossier development, submissions

200+

Real-world data & clinical studies

Our founders

Senior-led, partner-accountable

The partners you meet are the partners who lead your engagement. Every engagement is owned by a founder.
Meet the team
Fayaz Aziz Headshot Image

Fayaz Aziz

Managing Director, HTA/HEOR and Market Access

HEOR & market access · MPH, MSc, DrPH(c)
Dr Razia Headshot Image

Dr. Razia Hussain

Director, Medical Affairs

DBA, MBA, Mcert, HR, BSc

Start with the GCC Value Story Diagnostic

Whichever door you walk through, the same senior partner walks the journey with you. We begin with a diagnostic, then scope the work.
Book Your Diagnostic

Get GCC Access Insights

Practical thinking on registration, HTA, pricing and clinical adoption across the GCC, plus details of upcoming Veridian events.

Ajaz Rashid

Medical affairs & scientific communications

Over 30 years in medical affairs, scientific communications and clinical research in global, regional and local roles. Successful track record in leading people and teams to develop and deliver scientific narratives, programmes and content with demonstrable HCP impact across multiple therapeutic areas including respiratory, immunology, oncology, CV, metabolic, neurology and hepatology.

Dr. Rashmi Hegde

Medical affairs

30 years delivering 80+ Life Sciences product & vaccine regulatory approvals for launches across therapies and geographies. Expertise in Pharmacovigilance, Medical, Clinical, patient affairs, and medical governance. Optimized MA & MSL capabilities, focusing on executional excellence. Achieved 100% PV compliance across 33 global affiliates

Dr. Laura Jotimliansky

Medical affairs & clinical research

30+ years in pharma across multiple TAs and geographies. Internal Medicine and Clinical Pharmacology training with deep LATAM and Middle East focus. At GSK, led regional teams and built Oncology structure across Emerging Markets. Previously at BMS and Roche.

Dr. Elif Coskuncay

Medical affairs

25+ years spanning pharma, clinical practice, and strategic medical affairs at global, regional, and local levels. Therapeutic expertise in oncology, cardiovascular, metabolic, respiratory, rare diseases, and vaccines. Successfully launched life-saving therapies including immuno-oncology in emerging and developed markets.

Rafa Al Khalifa

Market access & stakeholder engagement

Healthcare strategy consultant specializing in specialty pharmacy, market access, patient support programs, health economics, quality, and compliance. UAE MOHAP-registered pharmacist. Led the first ACHC-accredited specialty pharmacy outside the US. FIP SAPS Executive Committee member; represented FIP at the World Health Assembly and COP29. Co-Founder of EcoRx UAE.

Dr. Claudia Soares

Rwe, heor & business intelligence

Physician with MSc/PhD in Epidemiology & Biostatistics and a Master’s in Business Intelligence (focused on AI in healthcare). Over 18 years of experience across academia, government, and the pharmaceutical industry in R&D, Health Outcomes, and Medical Affairs. Led global, regional, and local projects in clinical development, launch planning, epidemiology, health outcomes, real-world data (RWD), and evidence generation, with a strong track record of impact in emerging markets.

Dr. Ali AlHammad

Heor & market access

HEOR expert with strong background in market access, patient-reported outcomes, and medical research. Proven track record developing strategic brand plans for successful launches in Saudi Arabia. Deep understanding of the Saudi healthcare system, translating complex economic data into actionable insights for payers.

Safinaz Issa

Regulatory affairs & market access

Senior Regulatory, Government Affairs & Market Access Executive with 25+ years of leadership across Pfizer, GSK, Sanofi Genzyme, Novartis, Eisai, and Eli Lilly. Led 1,000+ filings and market access strategies across 40+ markets in MEA, Europe, and North America. Expertise spans regulatory strategy and intelligence, health authority engagement, compliance, lifecycle management, and complex product launches across rare diseases, neuroscience, oncology, and medical devices.

Dr. Razia Hussain

Director, Medical Affairs

Senior Medical Affairs and Clinical Research leader with 25+ years of international pharmaceutical experience across Oncology, Immunology, Cardiovascular, Respiratory, HIV, Hepatology, and Specialty Medicine. Led Medical Affairs teams in China and clinical research operations globally, delivering registration studies, evidence generation, pre-launch readiness, and RWE programmes. Developed medical excellence capabilities adopted as global best practices, led a major cardiovascular RWE study in the Middle East, and established a regional pharmacovigilance hub for Africa. Strong track record in medical strategy, cross-functional leadership, stakeholder engagement, and building high-performing teams.

Fayaz Aziz

Managing Director, HTA/HEOR and Market Access

Senior health economics, market access, and medical affairs leader with 25+ years of international experience spanning industry, government, academia, and consultancy across R&D, EU, Emerging Markets, and the Middle East. Led HEOR strategy and medical excellence across 30+ markets at GSK, delivered HTA submissions to NICE and SMC at Pfizer UK, and founded a global HEOR Academy that trained 2,000+ professionals. 15+ years in the GCC, with early career foundations as a public health scientist at the England Department of Health, health policy training at LSE, and doctoral research at LSHTM on AI governance in HTA decision-making.